SV Health Investors is a specialist healthcare fund manager that invests across multiple stages and sectors, utilizing strategy-specific funds. Their investment focus spans therapeutics (including biotechnology and dementia), healthcare growth, and medtech, aiming to identify and support promising healthcare ventures.
58% of their portfolio is in Biotech & Life Sciences. Deal activity increased 50% year-over-year (3 deals in the last 12 months). Average disclosed round size is $59.0M (across 12 rounds with reported amounts).
Portfolio
12
Fund Size
$4B
Top Stage
Series B
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Artios Pharma Limited | Series D | $115M | Nov 2025 |
 Dualitas Therapeutics, Inc. | Series A | $65M | Sep 2025 |
 Imbria Pharmaceuticals | Series B | $57.5M | Apr 2025 |
| CCSA Medical Inc. | Series D | $53M | Sep 2024 |
| BBrixton Biosciences | Series B | $33M | May 2024 |
 CarePredict | Series A | $29M | Jul 2023 |
| HHealth Payment Systems, Inc. (HPS)/PayMedix | Series B | $25M | Jan 2023 |
 Ria Health | Series A | $18M | Jun 2022 |
| Artios Pharma Limited | Series C | $153M | Jul 2021 |
 Sitryx Therapeutics | Series A | $30M | Oct 2018 |
 Endotronix, Inc. | Series D | $45M | Sep 2018 |
| Artios Pharma Limited | Series B | $84M | Aug 2018 |
Top Co-Investors
Andera Partners3 shared
LSP3 shared
Pfizer Ventures3 shared
Novartis Venture Fund3 shared
M Ventures3 shared
Sofinnova Partners3 shared
Deep Track Capital2 shared
RA Capital Management2 shared
Omega Funds2 shared
Avidity Partners2 shared
Invus2 shared
Schroders Capital2 shared
SVB Capital1 shared
Ascension Ventures1 shared
Blue Heron Capital1 shared
TVM Capital Life Science1 shared
First Analysis1 shared
Catalio Capital Management1 shared
Schooner Capital1 shared
Spartan Group1 shared
Last updated: 13 March 2026